Skip Ribbon Commands
Skip to main content
Menu
Dr Ravindran Kanesvaran from National Cancer Centre Singapore

Dr Ravindran Kanesvaran

MRCP (UK), BSc (Hons), MD, FAMS (Med Onco)

Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Uro-Oncology, Thoracic, Geriatric Medicine

Conditions Treated by this Doctor:
Thoracic Cancers, Uro-oncology.

Clinical Appointments

  • Consultant SingHealth Duke-NUS Lung Centre
  • Consultant NCCS Oncology @ SKH Sengkang General HospitalSengkang General Hospital
  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Assistant Professor

Profile

Dr Ravindran Kanesvaran is a Senior Consultant in the Division of Medical Oncology of the National Cancer Centre Singapore. He is also an Assistant Professor at Duke-NUS Graduate Medical School and clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is a core faculty member of the Medical Oncology Senior Residency Program and the Singhealth Internal Medicine Residency Program.He completed his medical oncology speciality training in the National Cancer Centre Singapore. After completion of that training he followed up with a fellowship in genitourinary oncology (GU) and geriatric oncology in Duke Cancer Institute in North Carolina, USA on a Healthcare Manpower Development Program (HMDP) scholarship awarded by the Ministry of Health Singapore. His research interests include GU oncology and geriatric oncology. He has published in a number of well-known peer reviewed journals including Journal of Clinical Oncology and Lancet Oncology.

He has also been awarded a number of awards including the American Society of Clinical Oncology (ASCO GU) Merit Award 2009, American Association for Cancer Research (AACR) scholar-in-training Award 2010 and European Society of Medical Oncology (ESMO) fellowship award 2012. He is currently the President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He has been appointed as European Society of Medical Oncology (ESMO) Faculty 2015-2016. He is on the Scientific and Education Committee and the National Representative for Singapore in the International Society of Geriatric Oncology (SIOG). He was awarded National Representative of the Year SIOG 2014 award.

Education

  • FAMS (Med Oncol) 
  • M.R.C.P. (UK) 
  • Doctor of Medicine (MD) 
  • Bachelor of Medical Sciences (Hons) 

Professional Appointments and Committee Memberships

  • Senior Consultant, National Cancer Centre Singapore 
  • Clinical Senior Lecturer, Yong Loo Lin School of Medicine, National University of Singapore 
  • Assistant Professor, Duke-NUS Graduate Medical School 
  • Visiting Consultant , Changi General Hospital ( CGH) 
  • Code Blue Committee 2012- to 2017 
  • MRCP Paces Communications Course Chair 2013 to 2017 
  • Singhealth- DUKE Scientific Congress Committee Member 2016 
  • Core Faculty and Chair of Program Evaluation Committee, Medical Oncology Senior Residency Program (NCCS) 
  • Core Faculty Internal Medicine Residency Program (Singhealth) 
  • Drugs Advisory Committee (Oncology Drugs Subcommittee ): Member 
  • Workgroup for ACP Implementation in Outpatient Setting
  • President , Singapore Society of Oncology 
  • President , Singapore Geriatric Oncology Society 
  • Board Member and Hon Treasurer , International Society of Geriatric Oncology ( SIOG) 
  • Fellow Academy of Medicine Singapore (FAMS) 
  • Member and Faculty , European Society of Medical Oncology ( ESMO) 
  • Singapore Cancer Society : Council Member 
  • Singapore Cancer Society: Cancer Rehab Committee Member 

Awards

  • Journal of Geriatric Oncology Reviewer of the Year Award 2014 
  • Singapore Health Quality Service Award 2015 (Best Team Award)
  • International Society of Geriatric Oncology (SIOG) National Representative of the Year 2014 Award 
  • Singhealth Outstanding Faculty Award (Academic Year 2013/2014) 
  • European Society of Medical Oncology (ESMO) Fellowship Award 2012 
  • Duke University School of Medicine Donald W. Reynolds Scholarship (mini-fellowship in Long Term Care Education) 
  • Healthcare Manpower Development Plan (HMDP) Scholarship (Ministry of Health Singapore) 2011
  • Singapore General Hospital Annual Scientific Meeting 2011 Young Investigator Award (Finalist) 
  • American Association for Cancer Research (AACR) Scholar-in- Training Award 2010
  • American Society of Clinical Oncology (ASCO) Cancer Foundation Merit Award 2009 (Genitourinary Symposium) 
  • Eli Lilly Orthopaedic Prize 2003 (Distinction in Orthopaedics) 
  • Malaysian Medical Association (MMA) Gold Medallist 2003 
  • ASEAN Secondary and Pre-university Scholarships awarded by Ministry of Education Singapore (1992-1997)

Publications and Research Trials

  • Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients. Marvalim C, Wong JX, Sutiman N, Lim WT, Tan SW, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Tan EH, Chowbay B. Pharmacogenet Genomics. 2017 Jan 2. doi: 10.1097/FPC.0000000000000266. [Epub ahead of print] 
  • Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanesvaran R, Choueiri TK, Heng DY. Eur Urol. 2017 Feb;71(2):204-209.
  • Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Choudhury Y, Toh YC, Xing J, Qu Y, Poh J, Huan L, Tan HS, Kanesvaran R, Yu H, Tan MH. Sci Rep. 2017 Jan 25;7:41238. doi: 10.1038/srep41238 
  • Cultural influences upon advance care planning in a family-centric society.Tay K, Yu Lee RJ, Sim SW, Menon S, Kanesvaran R, Radha Krishna LK. Palliat Support Care. 2017 Feb 8:1-10. doi: 10.1017/S1478951516001139. [Epub ahead of print] PMID: 28173885 
  • Discontinuing VEGF-Targeted Therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second line therapies in metastatic Renal Cell Carcinoma (mRCC).IMDC , R Kanesvaran, et al. Clin Genitourin Cancer. 2017 (in press) 
  • Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer. Ang JW, Ng QS, Toh CK, Tay MH, R Kanesvaran. Ann Acad Med, 2017 (in press) 
  • A comparison of attitudes toward length and quality of life between community dwelling older adults and patients with advanced cancer. Malhotra C, Xiang L, Ozdemir S, Kanesvaran R, Chan N, Finkelstein EA. Psychooncology. 2016 Dec 10. doi: 10.1002/pon.4344. [Epub ahead of print] 
  • Metronomic Chemotherapy: A Relook At Its Basis and Rationale. Rajasekaran T, Ng QS, Shao-Weng Tan D, Lim WT, Ang MK, Toh CK, Chowbay B, Kanesvaran R, Tan EH. Cancer Lett. 2016 Dec 18. pii: S0304-3835(16)30766-2. doi: 10.1016/j.canlet.2016.12.013. [Epub ahead of print] 
  • EGFR mutation subtypes influence survival outcomes following first-line gefitinib therapy in advanced Asian NSCLC patients. Sutiman N, Tan SW, Tan EH, Lim WT, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Chowbay B. J Thorac Oncol. 2016 Nov 28. pii: S1556-0864(16)33533-X. doi: 10.1016/j.jtho.2016.11.2225. [Epub ahead of print] 
  • The Complexities of Doctor-Patient-Family Communication in an Asian Oncology Setting: Concordance and Discordance Among Patient Preferences, Family Preferences, and Perceived and Actual Communication. Lee GL, Teo I, Kanesvaran R. Health Commun. 2016 Nov 30:1-7. [Epub ahead of print]

Research Trials

  • A Phase III, Multicenter, Randomized, Placebo-controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination with Platinum-based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma (WO30070), 2017 
  • A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma (WO29637), 2016 
  • AR-V7 Splice Variant in Asian Patients with Castration-Resistant Prostate Cancer (CRPC), 2015 
  • A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer (MK 3475-052), 2015 
  • A Phase III Randomized Trial of Pembrolizumab (MK-3475) versus Paclitaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer (MK3475-045), 2015 
  • A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), 2013 
  • Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors (GU09-145), 2012 
  • Development of a Clinic-Genomic Model Using Comprehensive Geriatic Assessment (CGA) and Identification of Genetic Factors in Elderly Cancer Patients in Singapore, 2010 
  • A Genitourinary Cancer Clinical Database and Specimen Archive for the National Cancer Centre Singapore and Singapore General Hospital, 2009